With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

In addition to requests for double-digit premium increases, Blue Cross Blue Shield of Vermont is also cutting back on coverage of popular weight-loss drugs on some plans.

President Donald Trump signed an executive order May 12 directing drugmakers to sell medicines in the U.S. at prices similar to those offered in other wealthy countries, or face penalties and ...

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge Eli Lilly ... adults was inline with expectations, allaying some concerns over elevated medical costs. UnitedHealth Group ...

Major benchmarks are down this year amid concerns about import tariffs and their impact on ... and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market ...

Company to host conference call and webcast today at 8:00 a.m. ET--MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc.

This article was provided by Mary Washington Healthcare, a corporate sponsor of the Fredericksburg Free Press. As part of its ...